Renvela: new phosphate binder formulation

Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.
Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.

Genzyme has launched Renvela, a new version of the phosphate binder sevelamer.

Sevelamer is a crosslinked polymer that binds phosphate molecules in the intestine.

Renvela contains the carbonate salt of the drug, whereas the existing formulation Renagel contains sevelamer hydrochloride.

Both are licensed for the treatment of hyperphosphataemia in patients on dialysis. Renvela is also licensed for use in patients with chronic kidney disease not on dialysis.

Two randomised controlled trials in the haemodialysis setting (one in 79 patients, the other in 31 patients) demonstrated the equivalence of sevelamer carbonate tablets and powder, respectively, to sevelamer hydrochloride tablets for serum phosphate control.

View Renvela drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases